This trial is evaluating whether OTS167PO will improve 1 primary outcome in patients with Triple Negative Breast Neoplasms. Measurement will happen over the course of During Cycle1 after the first administration.
This trial requires 70 total participants across 1 different treatment group
This trial involves a single treatment. OTS167PO is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"A single dose of ots167po with radiotherapy is safe and feasible and may be combined with any other treatment. The most frequent adverse reactions were local irritations and local hyper-pigmentation." - Anonymous Online Contributor
"There are no data available demonstrating that cure can be declared for specific cancers, but there are plenty of studies to suggest a reduction of incidence rates." - Anonymous Online Contributor
"Breast cancer, often abbreviated 'BC', is the most common cancer among women in the United States. It is the tenth leading cause of cancer deaths in the United States, with an annual rate of 2.5 new cases per 100,000 persons, and the most common type of cancer among women in the United States, with an annual rate of more than one per 100,000 people.\n" - Anonymous Online Contributor
"There are many risk factors with varying effects; an increasing number of cases has raised concerns about global warming. Cancer researchers have proposed a number of hypotheses with limited evidence supporting them, including environmental carcinogens, the genetic makeup of the person, diet and exposure to chemical and physical agents. The [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) hypothesis is probably the best supported hypothesis." - Anonymous Online Contributor
"About 90,300 men, women, and children annually are diagnosed with [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) in the United States. Breast cancer accounts for 15.4% of all cancer cases in women and for 7.2% in men. The incidence of breast cancer is highest in Caucasian women and in women whose families had a history of breast cancer. More information is needed to further investigate the racial variation in breast cancer incidence." - Anonymous Online Contributor
"The most frequently reported treatments for breast cancer include surgery, chemotherapy, hormonal therapy, radiation therapy, and targeted therapies, as well as combinations of these. When choosing appropriate treatment patterns, it is important to note the relative effectiveness of these treatments." - Anonymous Online Contributor
"Many [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) women report signs and symptoms that are typical of breast cancer including a lump in the breast, nipple itch, a new lump or a lump that becomes larger during palpation of the breast, nipple discharge or a change in the size or behavior of the breast. Patients should have their signs and symptoms reviewed by an experienced physician." - Anonymous Online Contributor
"Breast cancer is heritable. Breast cancer with an autosomal dominant pattern of inheritance is seen most often. Autosomal recessive inheritance of breast cancer occurs infrequently. The likelihood of breast cancer occurring in family members decreases as the number of affected family members increases." - Anonymous Online Contributor
"The interval between surgery for [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) and dissemination of the disease is very short with no evidence of survival in more than one-third of patients. The main contributors are early-stage, untreated tumours. The interval can be prolonged by early referral to a breast centre." - Anonymous Online Contributor
"Currently OTA167PO is used to treat prostate cancer but it has the potential for therapeutic use. We have studied several different dosing models to see if it would work for breast cancer. Data from a recent study suggest that the same dosing schedule is effective in breast cancer but, because the drug is known to be well tolerated, with many patients treated over decades, a schedule of once a week is probably the best. OTA167PO can be a useful tool for the treatment of breast cancer." - Anonymous Online Contributor
"In a recent study, findings indicated that the ots167po therapy is effective for the treatment of breast cancer and that such therapy is not toxic to the patients." - Anonymous Online Contributor
"Ots167po exhibited tolerability with no unexpected side effects. Mild stomatitis was a common adverse event; this was mild and transient and was reported by only one patient in each treatment arm." - Anonymous Online Contributor